Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients
出版年份 2019 全文链接
标题
Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients
作者
关键词
-
出版物
Cancers
Volume 11, Issue 1, Pages 93
出版商
MDPI AG
发表日期
2019-01-16
DOI
10.3390/cancers11010093
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer
- (2018) Jin-Young Jang et al. ANNALS OF SURGERY
- The Systemic-Immune-Inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels
- (2018) Mohammad Hosein Aziz et al. ANNALS OF SURGERY
- HALO-109–301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer
- (2018) Gary J Doherty et al. Future Oncology
- Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.
- (2018) Thierry Conroy et al. JOURNAL OF CLINICAL ONCOLOGY
- Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib
- (2018) Mi Young Jeon et al. LIVER INTERNATIONAL
- MutantKRASCirculating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring
- (2018) Ruth Perets et al. ONCOLOGIST
- Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma
- (2018) Janet E. Murphy et al. JAMA Oncology
- FOLFIRINOX Chemotherapy in Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Retrospective and Phase II Studies
- (2018) Stephane Thibodeau et al. Journal of Clinical Medicine
- Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
- (2018) Lilian Schwarz et al. BMC CANCER
- PRIMUS-001: An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation (ISRCTN75002153) – Part of Precision-Panc.
- (2018) Janet Shirley Graham et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients
- (2017) He Cheng et al. INTERNATIONAL JOURNAL OF CANCER
- The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients
- (2017) Matteo Piciucchi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma
- (2017) Çiğdem Usul Afsar et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial)
- (2017) Ken-ichi Okada et al. ONCOLOGY
- Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial
- (2017) Knut Jørgen Labori et al. BMC Surgery
- Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer
- (2017) Eveline E. Vietsch et al. Cancer Genetics
- lncRNA MALAT1, HOTTIP and PVT1 as predictors for predicting the efficacy of GEM based chemotherapy in first-line treatment of pancreatic cancer patients
- (2017) Cui-Juan Wang et al. Oncotarget
- Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer
- (2017) Yuan Gao et al. Oncotarget
- Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer
- (2017) Hyeong Seok Kim et al. Annals of Surgical Treatment and Research
- Evolving treatment landscape for early and advanced pancreatic cancer
- (2017) Sally C Lau et al. World Journal of Gastrointestinal Oncology
- Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer
- (2017) Marzia Del Re et al. Scientific Reports
- CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weeklynab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
- (2016) E. G. Chiorean et al. ANNALS OF ONCOLOGY
- Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer
- (2016) Naoto Hadano et al. BRITISH JOURNAL OF CANCER
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
- (2016) Mustafa Suker et al. LANCET ONCOLOGY
- Long Noncoding RNA MALAT1 Promotes Aggressive Pancreatic Cancer Proliferation and Metastasis via the Stimulation of Autophagy
- (2016) L. Li et al. MOLECULAR CANCER THERAPEUTICS
- Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma
- (2016) Nicola Silvestris et al. OncoTargets and Therapy
- Circulating biomarkers to monitor cancer progression and treatment
- (2016) Suthee Rapisuwon et al. Computational and Structural Biotechnology Journal
- Circulating tumor cells (CTC) and KRAS mutant circulating free DNA (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer
- (2015) Julie Earl et al. BMC CANCER
- Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility
- (2015) M. Ignatiadis et al. CLINICAL CANCER RESEARCH
- Biomarker: Predictive or Prognostic?
- (2015) Karla V. Ballman JOURNAL OF CLINICAL ONCOLOGY
- The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer
- (2015) Zhihua Li et al. Journal of Translational Medicine
- Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer
- (2015) Kjersti Tjensvoll et al. Molecular Oncology
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?
- (2014) K. K. Christians et al. ONCOLOGIST
- A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer
- (2014) Kelvin Chan et al. PLoS One
- Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer
- (2014) Henriette Golcher et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer
- (2014) Er-Jun Pang et al. TUMOR BIOLOGY
- Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer
- (2013) S Boeck et al. BRITISH JOURNAL OF CANCER
- Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies
- (2013) K. Sideras et al. CANCER TREATMENT REVIEWS
- Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy
- (2013) Christin Wittwer et al. INTERNATIONAL JOURNAL OF CANCER
- Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients
- (2013) Christin Wittwer et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy
- (2013) Koichiro Tsutsumi et al. PANCREATOLOGY
- Pathology and Molecular Genetics of Pancreatic Neoplasms
- (2012) Laura D. Wood et al. CANCER JOURNAL
- Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma
- (2012) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1
- (2012) Daniela Muenzel et al. Radiology and Oncology
- Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome
- (2012) BARBARA VIZIO et al. Experimental and Therapeutic Medicine
- Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells
- (2011) Lei You et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Pretreatment Carbohydrate Antigen 19-9 Level Indicates Tumor Response, Early Distant Metastasis, Overall Survival, and Therapeutic Selection in Localized and Unresectable Pancreatic Cancer
- (2011) Tae Yoo et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Carcinoembryonic antigen (CEA) as tumor marker in lung cancer
- (2011) M. Grunnet et al. LUNG CANCER
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-mobility group box 1 and cancer
- (2010) Daolin Tang et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer
- (2010) Motofumi Tanaka et al. CANCER
- Dynamic Behavior and Function of Foxp3+ Regulatory T Cells in Tumor Bearing Host
- (2010) F Xiao-Feng Qin Cellular & Molecular Immunology
- Significant Associations of Mismatch Repair Gene Polymorphisms With Clinical Outcome of Pancreatic Cancer
- (2009) Xiaoqun Dong et al. JOURNAL OF CLINICAL ONCOLOGY
- Long non-coding RNAs: insights into functions
- (2009) Tim R. Mercer et al. NATURE REVIEWS GENETICS
- Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study
- (2008) B. Chauffert et al. ANNALS OF ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- CA 19-9 as a Predictor for Response and Survival in Advanced Pancreatic Cancer Patients Treated With Chemoradiotherapy
- (2008) Woong Sub Koom et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now